NCT02223975

Brief Summary

Can vibrational spectroscopy be used to accurately assess vulval skin conditions? Vulval skin disorders are common and the diagnosis of these conditions can be difficult. Reliable discrimination between benign vulval skin conditions, precancerous conditions or vulval cancer often requires tissue biopsies. In addition the monitoring of patients with vulval disease at risk cancerous change is currently limited to visual assessment often supplemented by multiple invasive tissue biopsies. There are currently no established non invasive tests available for the diagnosis of vulval skin diseases. The vibrational spectroscopic techniques of Raman spectroscopy and Fourier transform infrared spectroscopy are non invasive diagnostic tools that use the interaction of light within tissues to identify the chemical composition of different tissues. The use of these tools may reduce the need for invasive biopsies to diagnose and monitor women with vulval skin disease. The aim of this project is to explore the use of vibrational spectroscopic techniques in the diagnosis of vulval skin disease. This will be achieved by performing vibrational spectroscopy on samples of tissue previously taken from women with vulval skin disease treated at Gloucestershire Hospitals NHS Foundation Trust. The results of the spectroscopy will be compared with the routine tests and the accuracy of spectroscopy determined.

Trial Health

33
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Trial recruitment is currently suspended
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2014

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

August 21, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 22, 2014

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2018

Completed
Last Updated

August 4, 2017

Status Verified

August 1, 2017

Enrollment Period

4 years

First QC Date

August 21, 2014

Last Update Submit

August 3, 2017

Conditions

Keywords

Spectrum Analysis, vibrationalSpectrum Analysis, infraredSpectrum Analysis, RamanSpectrum AnalysisFourier transform infrared spectroscopyRaman probeOpticalDiagnosisCancerMultivariate analysisVulval Intraepithelial NeoplasiaVulvar NeoplasmVulvaVulvar Diseases

Outcome Measures

Primary Outcomes (2)

  • Diagnostic performance of vibrational spectroscopic techniques for differentiating key vulval tissue types

    * Normal vulval skin * Lichen Sclerosus * High grade dysplasia - Usual type ('Vulval Intraepithelial Neoplasia 2-3') * High grade dysplasia - Differentiated type ('Vulval Intraepithelial Neoplasia 2-3') * Squamous cell carcinoma

    2 years

  • Diagnostic performance of vibrational spectroscopic techniques for differentiating between normal and diseased lymph nodes in vulval carcinoma.

    Diagnostic performance of vibrational spectroscopic techniques for differentiating between normal and diseased lymph nodes in vulval carcinoma.

    2 years

Secondary Outcomes (1)

  • Diagnostic performance of vibrational spectroscopic techniques for differentiating other vulval tissue types

    2 years

Study Arms (1)

Vulval Disease

Patients who have undergone vulval skin biopsy or surgery for a vulval condition within Gloucestershire Hospitals NHS Foundation Trust.

Eligibility Criteria

Age16 Years - 120 Years
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who have undergone vulval skin biopsy or surgery for a vulval condition within Gloucestershire Hospitals NHS Foundation Trust.

You may qualify if:

  • Vulval skin tissue stored after routine histopathological analysis from women treated or investigated for a vulval skin condition.
  • Inguinofemoral lymph nodes stored after routine histopathological analysis from women treated for vulval cancer.

You may not qualify if:

  • Tissue specimens inadequate for analysis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gloucestershire Hospitals NHS Foundation Trust

Gloucester, Gloucestershire, GL1 3NN, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITH DNA

Histological sections of vulval and lymph node tissue.

MeSH Terms

Conditions

Lichen Sclerosus et AtrophicusCarcinoma, Squamous CellDiseaseNeoplasmsVulvar NeoplasmsVulvar Diseases

Condition Hierarchy (Ancestors)

Lichenoid EruptionsSkin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasms, Squamous CellPathologic ProcessesPathological Conditions, Signs and SymptomsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Research Fellow

Study Record Dates

First Submitted

August 21, 2014

First Posted

August 22, 2014

Study Start

August 1, 2014

Primary Completion

August 1, 2018

Study Completion

August 1, 2018

Last Updated

August 4, 2017

Record last verified: 2017-08

Locations